These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931 [TBL] [Abstract][Full Text] [Related]
31. From uncertainty to pathogenicity: clinical and functional interrogation of a rare Quinn EA; Maciaszek JL; Pinto EM; Phillips AH; Berdy D; Khandwala M; Upadhyaya SA; Zambetti GP; Kriwacki RW; Ellison DW; Nichols KE; Kesserwan C Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 30886117 [TBL] [Abstract][Full Text] [Related]
32. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965 [TBL] [Abstract][Full Text] [Related]
33. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations. Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465 [TBL] [Abstract][Full Text] [Related]
34. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816 [TBL] [Abstract][Full Text] [Related]
35. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995 [TBL] [Abstract][Full Text] [Related]
36. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982 [TBL] [Abstract][Full Text] [Related]
37. Genetic and functional analysis of a Li Fraumeni syndrome family in China. Hu H; Liu J; Liao X; Zhang S; Li H; Lu R; Li X; Lin W; Liu M; Xia Z; Qing G; Li JD Sci Rep; 2016 Jan; 6():20221. PubMed ID: 26818906 [TBL] [Abstract][Full Text] [Related]
38. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome. Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations. Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143 [TBL] [Abstract][Full Text] [Related]
40. Identification and Management of Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]